Retatrutide Clinical and Preclinical Evidence

Overview

Retatrutide (LY3437943) is a once-weekly subcutaneous peptide that acts as a simultaneous agonist at three receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR). The triple-agonist mechanism distinguishes it from dual agonists such as tirzepatide (GLP-1/GIP) and positions it as a next-generation candidate in obesity and metabolic disease pharmacology.

The compound has progressed through Phase 2 trials published in high-impact journals, with an extensive Phase 3 TRIUMPH program across obesity, type 2 diabetes (T2D), cardiovascular disease, and chronic kidney disease populations.

Randomized Controlled Trials

Phase 2: Obesity (Jastreboff et al., 2023)

The most cited Phase 2 evidence for retatrutide in obesity comes from a 48-week, randomized, double-blind, placebo-controlled, dose-finding trial published in the New England Journal of Medicine (PMID 37366315; DOI: 10.1056/NEJMoa2301972).

Study design. Adults with a BMI of 30 or greater (or 27 with at least one weight-related comorbidity) but without T2D were enrolled. Participants were randomly assigned to one of five retatrutide dose regimens (1 mg, 4 mg, 8 mg, or 12 mg, with different escalation schedules) or placebo, all given subcutaneously once weekly.

Key efficacy results:

• 1 mg dose: mean body weight change of approximately -8.7% at week 48.
• 4 mg dose: approximately -17.1% at week 48.
• 8 mg dose: approximately -22.8% at week 48.
• 12 mg dose: approximately -24.2% at week 48, with the weight-loss curve not yet plateauing at trial end.

The proportion of participants achieving at least 5%, 10%, and 15% body weight reduction was substantially higher in the retatrutide arms versus placebo across all doses. At the 12 mg dose, more than 90% of participants achieved 5% or greater weight loss, and approximately 75% achieved 15% or greater.

Secondary endpoints. Waist circumference, fasting glucose, fasting insulin, HOMA-IR, triglycerides, systolic blood pressure, and fasting LDL-cholesterol all showed statistically significant improvements in the higher-dose groups relative to placebo.

Safety. Gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most frequent treatment-emergent events, predominantly mild-to-moderate and most common during dose escalation. The incidence was dose-dependent. Heart rate increased modestly in treated participants, consistent with GLP-1 and glucagon receptor agonism. No cases of pancreatitis were adjudicated as drug-related. Injection-site reactions were uncommon.

Phase 2: Type 2 Diabetes (Rosenstock et al., 2023)

A parallel Phase 2 program evaluated retatrutide in adults with T2D, published in The Lancet (PMID 37385280).

Study design. A randomized, double-blind, placebo-controlled, dose-finding trial enrolling adults with T2D on stable background metformin. Retatrutide was studied at 0.5 mg, 4 mg, 8 mg, and 12 mg dose levels (with escalation protocols) versus placebo over 36 weeks.

Key efficacy results:

• HbA1c reduction from baseline: up to -2.02 percentage points at the highest doses versus -0.01 for placebo.
• Body weight reduction: up to approximately -16.9% at 12 mg, substantially greater than previous GLP-1 receptor agonist benchmarks in T2D populations.
• Fasting serum glucose, fasting insulin, HOMA-IR, and lipid parameters improved in a dose-dependent manner.

Cardiometabolic secondary endpoints. Retatrutide produced clinically meaningful reductions in triglycerides and non-HDL-cholesterol, and lowered systolic blood pressure by 4-8 mmHg at higher doses. These effects reflect the combined pharmacology of GLP-1 (insulin secretion, gastric emptying), GIP (fat metabolism), and glucagon (hepatic lipid oxidation, energy expenditure) receptor engagement.

Body composition substudy. A dedicated body composition substudy (PMID 40609566, The Lancet Diabetes & Endocrinology, 2025) analyzed dual-energy X-ray absorptiometry (DXA) data from participants enrolled in the T2D Phase 2 trial. Retatrutide reduced both total fat mass and visceral adipose tissue in a dose-dependent manner. Lean mass was partially preserved relative to the magnitude of weight loss, though absolute lean mass reductions were observed at higher doses.

Kidney Outcomes: Phase 2 Substudy

A substudy of the Phase 2 T2D trial (PMID 40630318, Kidney International Reports, 2025) evaluated urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) at 36 weeks. Retatrutide reduced UACR in a dose-dependent fashion. eGFR changes were small and within expected ranges for compounds causing weight loss and metabolic improvement. These observations provided the mechanistic rationale for dedicated CKD trials.

TRANSCEND-CKD Design

A Phase 3 trial (NCT06297603, N=320) is evaluating retatrutide versus placebo in adults with T2D and moderate-to-severe chronic kidney disease. The design rationale was published by Heerspink et al. in Nephrology, Dialysis, Transplantation (PMID 41160422, 2025). Primary completion is projected for late 2026.

Eating Behavior and Appetite: Secondary Analyses

Secondary analyses from the Phase 2 obesity trial examined patient-reported eating behaviors using validated instruments. A 2025 publication (PMID 40916752, Diabetes, Obesity and Metabolism) reported that retatrutide treatment was associated with reduced appetite, reduced cravings for high-fat foods, and improved eating control scores. A companion analysis (PMID 40735804) identified associations between treatment-related improvements in eating behaviors and the magnitude of body weight reduction, independent of dose level.

Lipid Biomarker Analysis

A biomarker substudy (PMID 40726454, Diabetes, Obesity and Metabolism, 2025) measured angiopoietin-like protein 3 (ANGPTL3) and ANGPTL8 concentrations in participants from the Phase 2 T2D trial. Retatrutide treatment produced sustained decreases in circulating ANGPTL3/8 levels that correlated with serum triglyceride reductions. ANGPTL3 and ANGPTL8 are inhibitors of lipoprotein lipase; their suppression may partly explain the triglyceride-lowering effect observed with retatrutide beyond what GLP-1 agonism alone would predict.

Phase 3 Program (TRIUMPH)

The TRIUMPH program is a multi-trial, industry-sponsored Phase 3 development program sponsored by Eli Lilly. All trials listed below were actively enrolling or in follow-up as of April 2026.

TRIUMPH-1 uses percent change in body weight from baseline to week 80 as its primary endpoint. TRIUMPH-5 directly compares retatrutide to tirzepatide (the approved dual agonist), which will provide the first head-to-head evidence on whether incremental glucagon receptor agonism translates to superior clinical outcomes. TRIUMPH-4 (osteoarthritis) completed primary data collection in late 2025; results had not been published as of April 2026.

The cardiovascular outcomes trial (NCT06383390, N=10,000) is a 4-year event-driven study with primary endpoints of major adverse cardiovascular events (MACE) and kidney outcomes. Its size and design are comparable to the SURMOUNT-CVOT precedent established for tirzepatide.

Systematic Reviews and Meta-Analyses

A 2024 systematic review and meta-analysis (PMID 39318607, Metabolism Open) pooled data from available retatrutide clinical trial reports. The analysis confirmed:

• Statistically significant reductions in body weight, HbA1c, fasting glucose, triglycerides, and blood pressure versus placebo across dose ranges.
• A consistent dose-response relationship for all metabolic outcomes.
• Gastrointestinal adverse events as the dominant safety signal, with rates comparable to those seen with high-dose semaglutide.

A 2026 network meta-analysis (PMID 41787737, Endocrinology, Diabetes and Metabolism) compared glucagon receptor agonist-containing regimens across randomized trials. Retatrutide showed numerically greater weight reduction and cardiometabolic improvement relative to GLP-1-only agents, though direct trial evidence for most pairwise comparisons remained absent pending TRIUMPH-5 data.

Preclinical In Vivo Evidence

Diet-Induced Obesity Models: Mechanistic Pharmacology

The foundational mechanistic study of the GIPR-GCGR co-agonism relevant to retatrutide was published in 2026 (PMID 41997446, Molecular Metabolism). Using diet-induced obese rodent models, simultaneous GIPR and GCGR agonism restored normal body weight through effects on energy expenditure and adiposity independent of simple caloric restriction. The study clarified that glucagon receptor activation contributes energy expenditure enhancement that complements the satiety and insulin-sensitizing effects of GLP-1 and GIP receptor engagement.

MASH Mouse and Hamster Models

A 2026 study (PMID 41741376, Obesity) tested retatrutide in diet-induced obese mouse and hamster models of metabolic-associated steatohepatitis (MASH). The compound reduced:

• Liver fat content (assessed by histology and liver weight).
• Markers of hepatic fibrosis (collagen content, alpha-smooth muscle actin).
• Plasma ALT and AST.
• Visceral and total fat mass.
• Triglycerides and total cholesterol.

The MASH-relevant hepatic effects were attributed to multiple mechanisms: reduced hepatic lipid delivery (from fat mass reduction and VLDL-TG lowering), direct glucagon receptor-mediated hepatic fatty acid oxidation, and GLP-1/GIP-mediated improvements in insulin sensitivity and hepatic glucose metabolism.

Triple Agonism in MC4R-Deficient Obesity

A 2026 study (PMID 41723268, International Journal of Obesity) examined the efficacy of GLP-1 analogs including semaglutide, tirzepatide, and retatrutide in melanocortin 4 receptor (MC4R)-deficient mice, a model of monogenic severe obesity. Retatrutide retained meaningful efficacy in MC4R-deficient animals, whereas GLP-1-only agonism showed blunted responses. This suggests that GIP and glucagon receptor contributions support weight loss through pathways that do not depend fully on intact MC4R signaling.

Triple Agonism and Breast Cancer Models

A 2025 preclinical study (PMID 39868848, Advanced Science) examined retatrutide in obese triple-negative breast cancer (TNBC) models. The compound overcame a therapeutic barrier in obese TNBC treatment by suppressing tumor-promoting metabolic signaling. The study used in vitro and in vivo xenograft models; clinical translation to oncology remains speculative and is not the focus of current development.

Multi-Omic Analysis of Adipose Tissue

A 2026 multi-omic study (PMID 41964043, Diabetology and Metabolic Syndrome) profiled transcriptomic and proteomic changes in adipose tissue from retatrutide-treated obese rodents. The compound alleviated adipose tissue fibrosis through metabolic reprogramming and tissue repair pathways. Differentially expressed genes included those regulating extracellular matrix remodeling, mitochondrial biogenesis, and adipokine secretion.

Evidence Synthesis: Receptor-Level Signal Pathways

The three-receptor mechanism of retatrutide produces overlapping and complementary metabolic signals. The diagram below summarizes the primary downstream pathway logic.

flowchart TD
    RET["Retatrutide\n(LY3437943)"]
    GLP1R["GLP-1 Receptor\n(pancreas, CNS, gut)"]
    GIPR["GIP Receptor\n(pancreas, adipose, bone)"]
    GCGR["Glucagon Receptor\n(liver, adipose, CNS)"]

    RET --> GLP1R
    RET --> GIPR
    RET --> GCGR

    GLP1R --> INS["Glucose-stimulated\ninsulin secretion"]
    GLP1R --> SAT["Central satiety\nsignaling"]
    GLP1R --> GE["Gastric emptying\ndelay"]

    GIPR --> ADIPFAT["Adipocyte\nlipid handling"]
    GIPR --> INS2["Incretin-amplified\ninsulin secretion"]
    GIPR --> BONE["Bone turnover\nmodulation"]

    GCGR --> HEPA["Hepatic fatty acid\noxidation"]
    GCGR --> EE["Energy expenditure\nenhancement"]
    GCGR --> HGP["Hepatic glucose\nproduction (fasted)"]

    INS --> GLYC["Glycemic control"]
    INS2 --> GLYC
    SAT --> WT["Body weight\nreduction"]
    GE --> WT
    ADIPFAT --> WT
    EE --> WT
    HEPA --> LIPID["Triglyceride\nand lipid lowering"]
    HGP --> GLYC

Evidence Gaps and Ongoing Questions

Several clinically relevant evidence gaps remain open as of April 2026:

1. Long-term cardiovascular outcomes. TRIUMPH-3 (obesity with CVD, N=1,800) and the cardiovascular outcomes trial (NCT06383390, N=10,000) are ongoing. Whether the cardiometabolic risk factor improvements observed in Phase 2 translate to reduced MACE incidence is unknown.

2. Head-to-head versus approved agents. TRIUMPH-5 (retatrutide vs. tirzepatide, N=800) is active but not yet reporting. Network meta-analysis comparisons carry the limitations of indirect comparisons.

3. Duration of weight loss maintenance. Phase 2 trials ran to 48 weeks (obesity) and 36 weeks (T2D). Whether the weight trajectory plateaus, continues, or reverses after 12 months, and what happens after treatment discontinuation, has not been reported from Phase 3 data.

4. Lean mass preservation. The body composition substudy (PMID 40609566) observed proportional lean mass losses; whether strategies such as resistance exercise or protein supplementation modify this outcome in the context of retatrutide therapy is not established.

5. MASH clinical outcomes. Preclinical MASH data (PMID 41741376) are promising, but dedicated clinical trials with histological endpoints have not reported results.

6. Regulatory approval status. Retatrutide had not received regulatory approval in any jurisdiction as of April 2026. The TRIUMPH primary completion dates cluster in 2026, placing a plausible NDA submission in 2027 at the earliest.

Summary of Evidence Levels

This page is research-educational reference content. It does not constitute medical advice, clinical guidance, or sourcing recommendations. All data cited are from peer-reviewed publications or registered clinical trial records as of April 2026.

See also

More on Retatrutide:

• Retatrutide research overview
• Retatrutide: Mechanism of action
• Retatrutide: Safety profile
• Retatrutide: Pharmacokinetics
• Retatrutide: Dose-response

Related peptide family:

• GLP Family

Pathway context:

• Incretin Axis (GLP-1, GIP)

Head-to-head comparisons:

• Semaglutide vs Retatrutide
• Tirzepatide vs Retatrutide